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Abstract. 
 
Androgens play an important role in the 
growth of prostate cancer, but the molecular mecha-
nism that underlies development of resistance to anti-
androgen therapy remains unknown. Cyclin E has now 
been shown to increase the transactivation activity of 
the human androgen receptor (AR) in the presence of 
its ligand dihydrotestosterone. The enhancement of AR 
activity by cyclin E was resistant to inhibition by the an-
tiandrogen 5-hydroxyﬂutamide. Cyclin E was shown to 
bind directly to the COOH terminus portion of the AB 
domain of the AR, and to enhance its AF-1 transactiva-
tion function. These results suggest that cyclin E func-
tions as a coactivator of the AR, and that aberrant
expression of cyclin E in tumors may contribute to per-
sistent activation of AR function, even during androgen 
ablation therapy.
Key words: cyclin E • androgen receptor • prostate 
cancer • coactivator • cell cycle
 
Introduction
 
Androgens play an important role in the development and
progression of prostate cancer, one of the leading causes
of cancer death in men (Parker et al., 1996). Prostate can-
cer initially is androgen-sensitive and responds well to an-
drogen ablation therapy, which is the standard treatment
for metastatic disease (Catalona, 1994). However, treat-
ment-resistant regrowth of tumors ensues within several
years, and the molecular mechanism that underlies such
resistance remains unknown. Androgens and estrogens
regulate the growth of hormone-responsive prostate and
breast cancer through the androgen receptor (AR)
 
1
 
 and
the estrogen receptor, respectively, both of which belong
to the nuclear receptor superfamily (Mangelsdorf et al.,
1995). Mutations in the AR gene have been detected in
metastatic hormone-independent prostate cancer (Taplin
et al., 1995), and such mutations may contribute to the al-
tered response of the receptor to the hormonal environ-
ment. However, mutation of the AR gene is a relatively
rare event and cannot account for the adaptive response of
most prostate tumors to endocrine therapy. Transfer of
human surgical specimens to SCID mice has revealed that
androgen-independent metastatic tumors are able to re-
gain hormone responsiveness in a different host (Klein et
al., 1997), an effect that might be mediated by cellular fac-
tors that modulate AR function in the nucleus.
The mitotic signal of androgens is thought to target ulti-
mately the cell cycle machinery. Estrogens (Planas-Siva
and Weinberg, 1997; Prall et al., 1998) and androgens (Lu
et al., 1997; Kokontis et al., 1998; Menjo et al., 1998) regu-
late the activity of cyclin-dependent kinases (Cdks) by
modulating the expression of cyclins or Cdk inhibitors,
thereby promoting progression through the G
 
1
 
–S transi-
tion of the cell cycle. In addition, evidence suggests that
the estrogen receptor binds directly to cyclin D1 (Neuman
et al., 1997; Zwijsen et al., 1997). Given the frequent over-
expression and amplification of the cyclin D1 gene in
breast cancer (Buckley et al., 1993; Keyomarsi and Pardee,
1993), it is thought that cyclin D1 may activate the estro-
gen receptor in breast tumors in a Cdk-independent man-
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ner. However, little is known of whether the AR also
binds directly to components of the cell cycle machinery
and of how such an interaction might modulate the trans-
activation activity of the AR in prostate cancer. We now
show that cyclin E potentiates the transactivation activity
of the AR, and that this effect is mediated predominantly
through the binding of cyclin E to the AB domain of the
receptor.
 
Materials and Methods
 
Plasmids
 
Full-length cDNAs for human cyclin E, cyclin D1, cyclin A, or Cdk2 were
inserted into the pcDNA3 vector and pVP16. A cDNA for mutant cyclin
E (R130A) was kindly provided by K. Nakayama (Medical Institute of
Bioregulation, Kyushu University, Japan). Full-length cDNAs for the hu-
man AR, estrogen receptor 
 
a
 
 (ER
 
a
 
), glucocorticoid receptor (GR), or
progesterone receptor (PR) were inserted into the mammalian expression
vector pSG5. The AB (amino acids 1–556) and EF (amino acids 624–918)
domains of AR were cloned in the pGEX(4T-1) vector. The reporter con-
structs pARE2-tk-chloramphenicol acetyltransferase (CAT) and pBL-
CAT8
 
1
 
/estrogen response element (ERE) were described previously
(Tsai et al., 1989). GAL4-AR(AB) and GAL4-AR(EF) were constructed
in the pM vector (CLONTECH Laboratories, Inc.).
 
Cell Culture, Transient Transfection, and CAT Assay
 
HeLa and MDAH041 cells were maintained in DME supplemented with
10% FBS, and LNCaP cells in RPMI 1640 supplemented with 10% FBS.
24 h before transfection, the culture medium was changed to DME (with-
out phenol red) supplemented with 5% charcoal-treated FBS. Transfec-
tions were performed by the calcium phosphate precipitation technique
with 8 
 
m
 
g of the androgen response element (ARE)–CAT reporter con-
struct, 3 
 
m
 
g of 
 
b
 
-galactosidase expression vector (as an internal control for
differences in transfection efficiency), 1 
 
m
 
g of AR expression vector, and 8
 
m
 
g of cyclin E expression vector. 2 
 
m
 
g of GAL4-AR(AB) or GAL4-
AR(EF), 4 
 
m
 
g of VP16–cyclin E vector, and 8 
 
m
 
g of the 17M
 
2
 
-G–CAT re-
porter plasmid were used for mammalian two-hybrid analysis. 18 h after
transfection, cells were rinsed in PBS and cultured in medium containing
ligands or vehicle. After an additional 18 h, the cells were harvested and
assayed for CAT and 
 
b
 
-galactosidase activities. CAT activity was normal-
ized on the basis of 
 
b
 
-galactosidase activity.
 
Northern Blot Analysis
 
Northern blot analysis was performed as described previously (Takeyama
et al., 1997). cDNA probes for prostate-specific antigen (PSA), AR, and
 
b
 
-actin were labeled with 
 
a
 
[
 
32
 
P]dCTP by Random Primer DNA Labeling
kit (TAKARA). Hybridization was performed according to the manufac-
turer’s instructions. BAS1500 (Fuji) was used for densitometric analyses
of mRNA bands.
 
Immunoprecipitation and Immunoblot Analysis
 
MDAH041 cells were transfected with expression vectors encoding cyclin
E and either full-length AR, or the AB or EF domain of AR, cultured in
the absence or presence of dihydrotestosterone (DHT), and lysed in IP
buffer (150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 0.1% Tween 20,
10% glycerol, 50 mM Hepes, pH 8.0, 2 
 
m
 
g/ml leupeptin, 100 
 
m
 
g/ml phenyl-
methylsulfonyl fluoride, 2 
 
m
 
g/ml aprotinin, 20 
 
m
 
g/ml trypsin inhibitor. For
immunoprecipitation, cell lysates (2 mg of protein) were incubated at 4
 
8
 
C
with antibodies to cyclin E (Santa Cruz Biotechnology) and then with pro-
tein A–agarose beads (Boehringer). Bead-bound proteins were separated
by SDS-PAGE on a 10% gel, transferred to nitrocellulose, and subjected
to immunoblot analysis with anti-AR(AN1-15; Affinity Bioreagents; N-20
and C-19, Santa Cruz Biotechnology) antibodies. Immune complexes
were detected with ECL reagents (Amersham Pharmacia Biotech).
 
GST Pull-down Assay
 
Glutathione S-transferase (GST), as well as GST fusion proteins contain-
 
ing AR(AB) or its deletion mutants were produced in 
 
Escherichia coli
 
 and
purified with glutathione-Sepharose beads (Amersham Pharmacia Bio-
tech). Cyclin E was synthesized in vitro in the presence of [
 
35
 
S]methionine
with a reticulocyte lysate system (Promega). The 
 
35
 
S-labeled cyclin E was
incubated in the presence of glutathione beads with GST or with GST fu-
sion proteins. Bead-bound proteins were then analyzed by SDS-PAGE
and autoradiography.
 
Results
 
Effect of Cyclin E on the Transactivation Activity of AR
 
To detect possible functional cross-talk between
the AR and cell cycle regulators, we transfected
MDAH041 human fibroblastic cells (which do not ex-
press an endogenous AR) with an AR expression vec-
tor, an ARE–CAT reporter construct, and expression
vectors encoding cyclins D1, E, or A. Cyclin E in-
creased the transactivation activity of the AR in the
presence of DHT in a dose-dependent manner (Fig. 1
A). Cyclin E did not increase CAT activity in the ab-
sence of cotransfection with the AR expression vector
(data not shown), indicating that this effect of cyclin E
is mediated through the AR. This effect was specific to
cyclin E; cyclin A did not affect CAT activity and cyclin
D1 induced a slight decrease in CAT activity (Fig. 1 B).
The amount of AR protein was not increased by over-
expression of cyclin E (Fig. 1 B).
Whereas the DHT-induced increase in CAT activity was
blocked by incubation of cells not expressing exogenous
cyclin with the antiandrogen, 5-hydroxyflutamide (5-OH-
F), the DHT-dependent transactivation activity of the AR
in cells expressing exogenous cyclin E was not completely
inhibited only in cells incubated with a 10,000-fold molar
excess of 5-OH-F (Fig. 1 B). Similar results were obtained
in HeLa cells (data not shown).
Although the GR and PR act through the same DNA el-
ement as the AR (Cato et al., 1988), the potentiation of
ARE-dependent transcription by cyclin E was specific to
that mediated by the AR; cyclin E did not increase the
transactivation activity of GR or PR in the presence of
their ligands (Fig. 1 B). Exogenous cyclin E did not affect
the estrogen-induced increase in transactivation activity of
ER
 
a
 
 (Fig. 1 C), whereas cyclin D1 increased ER
 
a
 
 activity,
as described previously (Neuman et al., 1997; Zwijsen et
al., 1997).
Stimulation of the transactivation activity of the AR
by cyclin E was also apparent when cells were blocked
at G
 
1
 
–S or M phases of the cell cycle by treatment with
hydroxyurea or nocodazole, respectively (Fig. 1 D),
suggesting that this effect of cyclin E is independent of
cell cycle progression. Overexpression of either wild-
type or a kinase-inactive mutant of Cdk2 blocked the
stimulation of AR activity by cyclin E, and a mutant
cyclin E (R130A) that lacks the ability to bind Cdk2
(Nakayama et al., 2000) increased AR activity to the
same extent as the wild-type protein (Fig. 1 D). Thus,
this effect of cyclin E appears to be mediated by the
free protein, rather than by the cyclin E–Cdk2 com-
plex.
The effect of cyclin E on the induction of an endogenous
androgen-responsive gene, PSA, was examined in human 
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Figure 1. Potentiation of the
transactivation activity of
the AR by cyclin E. A,
MDAH041 cells were co-
transfected with an AR ex-
pression vector, an ARE–
CAT reporter plasmid, and
the indicated amounts of a
cyclin E expression vector.
Cells were incubated in the
presence of 1 nM DHT for
18 h and then assayed for
CAT activity. Data in the top
are expressed as relative
CAT activity and are means
(SD of triplicates from a
representative experiment).
The bottom shows the re-
sults of autoradiography. B,
MDAH041 cells were co-
transfected with an expres-
sion vector for AR, GR, or
PR, an ARE–CAT reporter
plasmid, and an expression
vector for cyclins E, A, or
D1. Cells were incubated in
the absence or presence of 1
nM DHT (T), 1 nM dexa-
methasone (D), 1 nM proges-
terone (P), or 10 mM 5-OH-F
for 18 h and then assayed for
CAT activity (top). Cell ly-
sates (20 mg of protein) were
also subjected to immunoblot
analysis with anti-AR(N-20).
C, MDAH041 cells were
cotransfected with an ERa
expression vector and an
ERE–CAT reporter plasmid
in the absence or presence of
an expression vector for cy-
clins A, D1, or E. Cells were
incubated for 18 h in the ab-
sence or presence of 10 nM
17b-estradiol (E2) and then
assayed for CAT activity.
D, MDAH041cells were
cotransfected with an AR ex-
pression vector and an ARE–
CAT reporter plasmid in the
absence or presence of an ex-
pression vector (3 mg) for
wild-type (WT) or the
R130A mutant of (Mut) cy-
clin E, or of an expression
vector (5 mg) for wild-type (WT) or a kinase-inactive mutant (Mut) of Cdk2. Cells were incubated for 18 h in the presence of 1 nM DHT
and in the absence or presence of 1 mM hydroxyurea (HU) or nocodazole (Noc; 0.1 mg/ml, only added during the final 8 h of incuba-
tion). Flow cytometry revealed that .70% of cells were arrested at G1–S or M phases by hydroxyurea and nocodazole, respectively
(data not shown). E, LNCaP cells were transfected with a cyclin E expression vector or with the empty vector, and subsequently incu-
bated for 18 h in the presence of 10 nM DHT. The relative abundance of PSA, AR, and b-actin mRNAs as revealed by densitometric
scanning with the amount in cells not expressing exogenous cyclin E taken as 1.0 are indicated below each lane. The transfection effi-
ciency was estimated as z30% by counting the number of b-galactosidase–positive cells.
 
prostate tumor LNCaP cells (which express endogenous
ARs). Exposure of these cells to DHT induced a 12-fold
increase in the amount of PSA mRNA (data not shown).
Exogenous cyclin E potentiated this effect of DHT on
PSA gene expression by a factor of 2.7 (Fig. 1 E), without
affecting the abundance of endogenous AR or 
 
b
 
-actin
mRNAs, supporting the notion that cyclin E acts as a coac-
tivator of the AR. 
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Selective Activation of the AF-1 Function of AR by 
Cyclin E
 
The AR exhibits two transactivation functions that are
mediated by ligand-independent (AF-1) and ligand-
dependent (AF-2) activation domains located in the NH
 
2
 
-
terminal AB region and in the COOH-terminal ligand-
binding EF region, respectively (Langley et al., 1995;
Doesburg et al., 1997). To localize the domain of AR that
mediates the functional interaction with cyclin E, we per-
formed a mammalian two-hybrid assay with either the AB
or EF region of AR fused to the DNA-binding domain
(DBD) of GAL4 and HeLa cells cotransfected with a
GAL4-dependent reporter plasmid. The GAL4-AR(AB)
construct alone exhibited a constitutive transactivation ac-
tivity in the absence of DHT, reflecting its AF-1 function
(Fig. 2 A). Expression of either cyclin E alone (Fig. 2 A)
or a VP16–cyclin E fusion protein (data not shown) fur-
ther increased CAT activity in cells expressing GAL4-
AR(AB), but not GAL4-AR(EF). These results, together
with the observation that cyclin E by itself, when fused to
the GAL4 DBD, stimulated transcription (Fig. 2 B), sug-
gest that cyclin E not only interacts with the AB domain of
AR but also functions as a coactivator of the AR. Again,
in these experiments, the abundance of the AR was not af-
fected by overexpression of cyclin E (Fig. 2).
 
Binding of Cyclin E to the AB Domain of AR
 
To investigate further the physical association of cyclin E
with the AR in vivo, we transfected MDAH041 cells with
an expression vector for AR in the absence or presence of
vectors encoding cyclins E, D1, or A. Cyclin E immuno-
precipitates prepared from cells overexpressing full-length
AR and cyclin E yielded an intense band of AR on immu-
noblot analysis, the broadness of which was increased by
prior treatment of cells with DHT (Fig. 3 A). A faint AR
band was also detected in the immunoprecipitates pre-
pared from cells transfected with the AR vector alone,
presumably reflecting association between endogenous cy-
clin E and recombinant AR; again, exposure of cells to
DHT increased the broadness of the AR band, an effect
likely attributable to AR phosphorylation (Blok et al.,
1996). The AR was not detected in the cyclin A or cyclin
D1 immunoprecipitates prepared from transfected cells
incubated in the absence or presence of DHT (data not
shown), indicating that the AR binds specifically to cyclin
E in vivo.
The region of AR that physically interacts with cyclin E
Figure 2. Functional interaction of cyclin E
with the AB domain of the AR. A, HeLa
cells were cotransfected with 17M2-G-CAT,
GAL4-AR(AB), or AR(EF), and an ex-
pression vector for cyclin E. Cells were in-
cubated for 18 h in the absence or presence
of 1 nM DHT and then assayed for CAT
activity (top). Cell lysates (20 mg of pro-
tein) were also subjected to immuno-
blot analysis with anti-AR(N-20) or anti-
AR(C-19) as indicated (bottom). B, The
interaction between GAL4–cyclin E and
VP16-AR(AB) was examined in a similar
manner. Data in A and B are means (SD of
triplicates from a representative experi-
ment).
Figure 3. Physical association of cyclin E with the AB domain of
AR in vivo. MDAH041 cells were cotransfected with expression
vectors for cyclin E and for either full-length AR (A), the AB
(B), or EF (C) regions of the AR. Cells were incubated for 18 h
in the absence or presence of 1 nM DHT, lysed, and subjected to
immunoprecipitation (IP) with antibodies to cyclin E or with nor-
mal rabbit serum (NRS) as a control. The resulting immunopre-
cipitates were then subjected to immunoblot analysis with anti-
AR(N-20) (A and B) or anti-AR(C-19) (C). The first two lanes
of each represent direct immunoblot analysis of cell lysates. 
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in vivo was further examined by transfecting MDAH041
cells with expression vectors for cyclin E and for either the
AB or EF region of AR. Cyclin E immunoprecipitates
were then subjected to immunoblot analysis with antibod-
ies specific for either the NH
 
2
 
-terminal or COOH-termi-
nal region of AR, respectively. Whereas the AB domain of
AR was coimmunoprecipitated with cyclin E (Fig. 3 B),
the EF domain of AR was not (Fig. 3 C), indicating that
cyclin E associates predominantly with the AB domain of
AR. In these experiments, the abundance of the AB and
EF fragments of the AR was not affected by overexpres-
sion of cyclin E (data not shown).
Finally, we examined whether cyclin E binds directly
to the AB domain of AR and, if so, to which region of
AR(AB) it binds. GST fusion proteins containing AR(AB)
or various deletion mutants thereof (Fig. 4 A) were incu-
bated in vitro with 
 
35
 
S-labeled cyclin E and the associated
cyclin E was detected by SDS-PAGE and autoradiogra-
phy. Cyclin E directly bound to NH
 
2
 
-terminally truncated
mutants of AR(AB), but not to COOH-terminal trunca-
tion mutants (Fig. 4 D), indicating that the cyclin E-bind-
ing domain is located in the COOH-terminal portion of
AR(AB).
In agreement with the results of the in vitro binding as-
Figure 4. Localization of the
cyclin E-binding domain
within the AB region of AR.
A, HeLa cells were cotrans-
fected with a CAT reporter
plasmid containing GAL4
binding sites and an ex-
pression vector encoding
AR(AB) or its indicated dele-
tion mutants fused to the
GAL4 DBD, in the absence
(open bars) or presence
(closed bars) of an expression
vector for cyclin E. Cells were
subsequently lysed and as-
sayed for CAT activity. Data
are means (SD of triplicates
from a representative experi-
ment). B, Cell lysates (20 mg
of protein) were also sub-
jected to immunoblot analysis
with antibodies to AR: top,
anti-AR(N-20); bottom, anti-
AR(AN1-15). C, HeLa cells
were cotransfected with an
ARE–CAT reporter con-
struct and expression vectors
for either full-length AR or
the del.E mutant of AR, in
the absence or presence of a
cyclin E expression vector.
Cells were incubated for 18 h
in the absence or presence of
1 nM DHT and then assayed
for CAT activity. Cell lysates
(20 mg or protein) were also
subjected to immunoblot
analysis with anti-AR(C-19);
the arrowheads indicate the
positions of full-length AR
and the del.E mutant. D, GST
fusion proteins containing
AR(AB) or its various dele-
tion mutants were incubated
with 35S-labeled cyclin E in
vitro and bead-bound cyclin E
was detected by SDS-PAGE
and autoradiography. 
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say, cyclin E increased the transactivation activities of
NH
 
2
 
-terminal truncation mutants of AR(AB), but not
those of COOH-terminal truncation mutants (Fig. 4 A).
Deletion of the region encompassing amino acids 419–556
(mutant del.13) markedly inhibited the ability of cyclin E
to promote transcription (Fig. 4 A). The mutant AR pro-
teins were expressed at a level similar to that of AR(AB)
(Fig. 4 B). These results indicate that the binding of cyclin
E to the COOH-terminal portion (amino acids 419–556)
of AR(AB) is required for its ability to enhance the AF-1
function of the AR. Consistent with this notion, deletion
of both the cyclin E-binding region and the transactivation
domain from full-length AR (mutant del.E) prevented not
only activation of AR by DHT, but also the stimulatory ef-
fect of cyclin E on AR function in the presence of DHT
(Fig. 4 C).
 
Discussion
 
We have demonstrated a functional and physical interac-
tion between cyclin E and the AR. Of the various cyclins
tested, only cyclin E (not cyclins D1 or A) bound to the
AR and increased its transactivation activity. Further-
more, complex formation with Cdk2 was not required for
the interaction of cyclin E with the AR. Although the
transactivation function of nuclear hormone receptors is
modulated by phosphorylation (Kato et al., 1995), the AR
was not phosphorylated by the cyclin E–Cdk2 complex in
vitro (data not shown), rendering it unlikely that cyclin E
overexpression enhances AR function as a result of phos-
phorylation by cyclin E–Cdk2. Also consistent with this
notion are the observations that overexpression of a ki-
nase-inactive mutant of Cdk2 inhibited the stimulatory ef-
fect of cyclin E and that a mutant cyclin E that lacks the
ability to bind Cdk2 still enhanced AR function. Cyclin E
also appears to interact specifically with the AR among
the various nuclear hormone receptors tested; it thus did
not affect ER, GR, or PR-mediated gene transcription. Fi-
nally, coimmunoprecipitation analysis with transfected
cells and GST precipitation assays in vitro revealed that
cyclin E associates predominantly with the AB domain of
AR and that a cyclin E-binding domain is located in the
COOH-terminal portion of AR(AB). The importance of
this binding site in the enhancement of AR function by cy-
clin E was supported by the results of functional assays. To
date, only a few coactivators have been shown to interact
specifically with the AR and to enhance its transactivation
function. The coactivator ARA
 
70
 
 interacts with the EF do-
main of AR in a ligand-specific manner and enhances its
AF-2 function (Yeh and Chang, 1996), whereas SNURF
enhances not only AR-, GR-, and PR-mediated transacti-
vation, but also basal transcription (Moilanen et al., 1998).
Thus, cyclin E is a specific coactivator to be identified that
binds directly to the AB domain of AR and enhances its
AF-1 function.
Although the AR and estrogen receptor appear to inter-
act with distinct cyclins, a functional and physical interac-
tion between nuclear hormone receptors and components
of the cell cycle machinery may represent a general mech-
anism by which the transactivation function of these re-
ceptors is regulated through recruitment of coactivators.
From a clinical standpoint, our results suggest that the in-
 
appropriate activation of AR by cyclin E may underlie the
development of resistance of prostate cancer. Thus, it
would be of interest to study whether cyclin E is overex-
pressed in prostate cancer, especially in the transition to
the hormone-independent stage.
 
We thank D. Morgan, M. Ohtsubo, and K. Nakayama for expression vec-
tors, and J. Yanagisawa for discussion.
This work was supported in part by grants-in-aid for Cancer Research
(to E. Ogata and S. Kato) and for Scientific Research on Priority Areas
(to M. Nakanishi) from the Ministry of Education, Science, Sports and
Culture of Japan.
Submitted: 25 April 2000
Revised: 29 June 2000
Accepted: 3 July 2000
 
References
 
Blok, L.J., P.E. de Ruiter, and A.O. Brinkmann. 1996. Androgen receptor
phosphorylation. 
 
Endocrine Res.
 
 3:197–219.
Buckley, M.F., K.J. Sweeney, J.A. Hamilton, R.L. Sini, D.L. Manning, R.I.
Nicholson, A. de Fazio, C.K. Watts, E.A. Musgrove, and R.L. Sutherland.
1993. Expression and amplification of cyclin genes in human breast cancer.
 
Oncogene.
 
 8:2127–2133.
Catalona, W.J. 1994. Management of cancer of the prostate. 
 
N. Engl. J. Med.
 
331:996–1004.
Cato, A.C.B., P. Skroch, J. Weinman, P. Butkeraitis, and H. Ponta. 1988. DNA
sequences outside the receptor-binding sites differently modulate the re-
sponsiveness of the mouse mammary tumour virus promoter to various ste-
roid hormones. 
 
EMBO (Eur. Mol. Biol. Organ.) J.
 
 7:1403–1410.
Doesburg, P., C.W. Kuil, C.A. Berrevoets, K. Steketee, P.W. Faber, E. Mulder,
A.O. Brinkmann, and J. Trapman. 1997. Functional 
 
in vivo
 
 interaction be-
tween the amino-terminal, transactivation domain and the ligand binding
domain of the androgen receptor. 
 
Biochemistry.
 
 36:1052–1064.
Kato, S., H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Ma-
sushige, Y. Gotoh, E. Nishida, H. Kawashima, et al. 1995. Activation of the
estrogen receptor through phosphorylation by mitogen-activated protein ki-
nase. 
 
Science.
 
 270:1491–1494.
Keyomarsi, K., and A.B. Pardee. 1993. Redundant cyclin overexpression and
gene amplification in breast cancer cells. 
 
Proc. Natl. Acad. Sci. USA.
 
 90:
1112–1116.
Klein, K.A., R.E. Reiter, J. Redula, H. Moradi, X.L. Zhu, A.R. Brothman, D.J.
Lamb, M. Marcelli, A. Belldegrun, O.N. Witte, and C.L. Sawyers. 1997. Pro-
gression of metastatic human prostate cancer to androgen independence in
immunodeficient SCID mice. 
 
Nat. Med
 
. 3:402–408.
Kokontis, J.M., N. Hay, and S. Liao. 1998. Progression of LNCaP prostate tu-
mor cells during androgen deprivation: hormone-independent growth, re-
pression of proliferation by androgen, and role for p27
 
Kip1
 
 in androgen-
induced cell cycle arrest. 
 
Mol. Endocrinol
 
. 12:941–953.
Langley, E., Z.X. Zhou, and E.M. Wilson. 1995. Evidence for an anti-parallel
orientation of the ligand-activated human androgen receptor dimer. 
 
J. Biol.
Chem
 
. 270:29983–29990.
Lu, S., S.Y. Tsai, and M.-J. Tsai. 1997. Regulation of androgen-dependent pros-
tatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16
genes. 
 
Cancer Res.
 
 57:4511–4516.
Mangelsdorf, D.J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono,
B. Blumberg, P. Kastner, M. Mark, and P. Chambon. 1995. The nuclear re-
ceptor superfamily: the second decade. 
 
Cell.
 
 83:835–839.
Menjo, M., Y. Kaneko, E. Ogata, K. Ikeda, and M. Nakanishi. 1998. Critical
role for p27
 
Kip1
 
 in cell cycle arrest after androgen depletion in mouse mam-
mary carcinoma cells (SC-3). 
 
Oncogene.
 
 17:2619–2627.
Moilanen, A.-M., H. Poukka, U. Karvonen, M. Hakli, O.A. Janne, and J.J.
Palvimo. 1998. Identification of a novel RING finger protein as a coregula-
tor in steroid receptor-mediated gene transcription. 
 
Mol. Cell. Biol
 
. 18:5128–
5139.
Nakayama, K., H. Nagahama, Y.A. Minamishima, M. Matsumoto, I. Nakami-
chi, K. Kitagawa, M. Shirane, R. Tsunematsu, T. Tsukiyama, N. Ishida, et al.
2000. Targeted disruption of Skp2 results in accumulation of cyclin E and
p27Kip1, polyploidy and centrosome overduplication. 
 
EMBO (Eur. Mol.
Biol. Organ.) J. 
 
19:2069–2081.
Neuman, E., M.H. Ladha, N. Lin, T.M. Upton, S.J. Miller, J. DiRenzo, R.G.
Pestell, P.W. Hinds, S.F. Dowdy, M. Brown, and M.E. Ewen. 1997. Cyclin
D1 stimulation of estrogen receptor transcriptional activity independent of
cdk4. 
 
Mol. Cell. Biol
 
. 17:5338–5347.
Parker, S.L., T. Tong, S. Bolden, and P.A. Wingo. 1996. Cancer statistics. 
 
CA
Cancer J. Clin.
 
 46:5–27.
Planas-Siva, M.D., and R.A. Weinberg. 1997. Estrogen-dependent cyclin E-Cdk2
activation through p21 redistribution. 
 
Mol. Cell. Biol
 
. 17:4059–4069.
Prall, O.W., E.M. Rogan, and R.L. Sutherland. 1998. Estrogen regulation of cell
cycle progression in breast cancer cells. 
 
J. Steroid Biochem. Mol. Biol
 
. 65: 
Yamamoto et al. 
 
Cyclin E As a Coactivator of the AR
 
879
 
169–174.
Takeyama, K., S. Kitanaka, T. Sato, M. Kobori, J. Yanagisawa, and S. Kato.
1997. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis.
 
Science.
 
 277: 1827–1830.
Taplin, M.-E., G.J. Bubley, T.D. Shuster, M.E. Frantz, A.E. Spooner, G.K.
Ogata, H.N. Keer, and D.P. Balk. 1995. Mutation of the androgen-receptor
gene in metastatic androgen-independent prostate cancer. 
 
N. Engl. J. Med
 
.
332:1393–1398.
Tsai, S.Y., M.-J. Tsai, and B.W. O’Malley. 1989. Cooperative binding of steroid
hormone receptors contributes to transcriptional synergism at target en-
hancer elements. 
 
Cell.
 
 57:443–448.
Yeh, S., and C. Chang. 1996. Cloning and characterization of a specific coactiva-
tor, ARA70, for the androgen receptor in human prostate cells. 
 
Proc. Natl.
Acad. Sci. USA.
 
 93:5517–5521.
Zwijsen, R.M.L., E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards,
and R.J. Michalides. 1997. CDK-independent activation of estrogen receptor
by cyclin D1. 
 
Cell.
 
 88:405–415.